

Hong Kong Exchanges and Clearing Limited and The Stock Exchange of Hong Kong Limited take no responsibility for the contents of this announcement, make no representation as to its accuracy or completeness and expressly disclaim any liability whatsoever for any loss howsoever arising from or in reliance upon the whole or any part of the contents of this announcement.



UMP HEALTHCARE HOLDINGS LIMITED

聯合醫務集團有限公司

(Incorporated in the Cayman Islands with limited liability)

(Stock Code: 722)

PROFIT WARNING

This announcement is made by UMP Healthcare Holdings Limited (the “**Company**” and together with its subsidiaries, the “**Group**”) pursuant to Rule 13.09 of the Rules Governing the Listing of Securities on The Stock Exchange of Hong Kong Limited (the “**Listing Rules**”) and the Inside Information Provisions (as defined in the Listing Rules) under Part XIVA of the Securities and Futures Ordinance (Chapter 571, Laws of Hong Kong).

The board of directors (the “**Board**”) of the Company wishes to inform the shareholders of the Company and potential investors that, based on the information currently available to the Board and the preliminary review of the unaudited management accounts of the Group, the Board expects that the net profit of the Company for the year ended 30 June 2019 will represent a significant decrease of approximately 55% as compared with the corresponding period for the year ended 30 June 2018. Such decrease is mainly attributable to the non-cash expense of a total of HK\$48 million incurred in connection with the granting of certain numbers of share options under the Post-IPO Share Option Scheme adopted by the Company on 2 November 2015 and the issuance of an aggregate of 110,411,000 Warrants and the vesting of 36,803,667 Warrants of the Company to Zheng He on 6 December 2018. Please refer to the announcements of the Company dated 27 July 2018, 30 August 2018 and 6 December 2018 and the circular of the Company dated 29 October 2018 (the “**Circular**”) for further details. Terms defined in the Circular shall have the same meanings when used in this announcement.

Based on the preliminary review of the unaudited management accounts of the Group, the Company expects to record a total revenue of approximately HK\$567 million and adjusted EBITDA (as defined in 2018 annual results announcement of the Company) of approximately HK\$85 million, representing a year on year increase of approximately 22% (as compared to the restated FY2018 revenue) and 31% respectively. The Company will provide additional breakdown of financial and operational information in its annual results announcement.

The Company has yet to finalise its annual results for the year ended 30 June 2019. The information contained in this announcement is only based on the preliminary review of the Company's management accounts with reference to the information currently available to the Board and is not based on any figures or information that has been audited or reviewed by the auditors or the audit committee of the Company. Shareholders and investors are advised to read carefully the annual results announcement of the Company for the year ended 30 June 2019, which is expected to be published before end of September 2019.

Shareholders and potential investors should exercise caution when dealing in the shares of the Company.

By Order of the Board
UMP Healthcare Holdings Limited
Sun Yiu Kwong
Chairman and Chief Executive Officer

Hong Kong, 23 August 2019

As at the date of this announcement, the board of directors of the Company comprises Dr. SUN Yiu Kwong as Chairman, Chief Executive Officer and executive director, Ms. KWOK Cheuk Kwan, Jacquen, as Managing Director and executive director, Mr. TSANG On Yip, Patrick, Dr. SUN Man Kin, Michael, Mr. LEE Kar Chung, Felix and Dr. LEE Pak Cheung, Patrick as executive directors, and Mr. LEE Luen Wai, John BBS JP, Dr. LI Kwok Tung, Donald SBS JP and Mr. YEUNG Wing Sun, Mike as independent non-executive directors.